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JOURNAL OF CLINICAL ONCOLOGY C O R R E S P O N D E N C E
Interim Fluorodeoxyglucose Positron
Emission Tomography–Adapted
Therapy Is Not an Efﬁcient Approach
to Improving Outcome in Early-Stage
Hodgkin Lymphoma
TO THE EDITOR: We read with interest the recent article in
Journal of Clinical Oncology by Andre´ et al,1 which included 1,950
patients with early-stage favorable or unfavorable Hodgkin lym-
phoma who underwent interim ﬂuorodeoxyglucose (FDG) posi-
tron emission tomography (PET) after two cycles of doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD). Depending on
the interim FDG-PET results, patients were randomly assigned to
continuation of ABVD therapy with involved-ﬁeld radiotherapy
(IFRT); intensiﬁed therapy with escalated doses of bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone (BEACOPP) and IFRT; or de-escalated
therapy with ABVD monotherapy without IFRT. After two cycles
of ABVD, interim FDG-PET was positive in 18.8% of patients
(13.0% with a favorable and 22.4% with an unfavorable risk
proﬁle). Treatment de-escalation in interim FDG-PET–negative
patients was considered infeasible because of the higher relapse
rate in patients treated without IFRT in both the favorable and
unfavorable Hodgkin lymphoma subgroups. Unfortunately,
subgroup analyses in interim FDG-PET–positive patients was
not performed “because of their presumed common poor
prognosis.”1(p1787) The 5-year progression-free survival (PFS)
rate was 77.4% in interim FDG-PET–positive patients treated
with standard treatment, with 36 of 192 (18.8%) patients
developing disease relapse during follow-up, whereas the 5-year
PFS rate was 90.6% in interim FDG-PET–positive patients
treated with escalated treatment, with 13 of 169 (7.7%) patients
developing disease relapse during follow-up, resulting in a risk
difference of 11.1%. Andre´ et al1 concluded that classic Eu-
ropean Organisation for Research and Treatment of Cancer
prognostic factors (eg, erythrocyte sedimentation rate, B
symptoms, age, and bulky disease) lose clinical relevance in the
era of FDG- PET–adapted therapy. They also concluded that
interim FDG-PET allowed for early treatment adaptation, but
only for treatment intensiﬁcation in interim FDG-PET–positive
patients, whereas a negative interim FDG-PET result was not
considered appropriate for omission of IFRT.
Although these results sound promising, we have several
comments. First, Andre et al’s claim that a positive interim
FDG-PET result guarantees a poor prognosis is untrue, because
this statement was simply not supported by their own data.
Note that patients with positive interim FDG-PET results had
a good 5-year PFS of 77.4% and high 5-year overall survival of
89.3% following continuation of standard therapies.1 Second,
we do not agree with the authors’ statement that classic risk
factors lose clinical signiﬁcance in the era of interim FDG-PET.
In the negative interim FDG-PET group, there was a remark-
able difference in PFS rates between patients with favorable
(5-year PFS, 99.0%) and unfavorable (5-year PFS, 92.1%) risk
proﬁles, despite the fact that patients with an unfavorable
risk proﬁle received more ABVD cycles. On the other hand,
a subgroup analysis of favorable versus unfavorable cases in
interim FDG-PET–positive patients was not performed. Con-
sequently, it remains unknown whether treatment escalation is
equally effective in these subgroups. The predictive value of
interim FDG-PET in these subgroups has not been described
previously, and omission of reporting these analyses results in
a major loss of valuable available data. Third, we believe that an
interim FDG-PET–adapted therapeutic approach is highly
inefﬁcient. Only 18.8% of patients will be positive at interim
FDG-PET, who will all receive intensiﬁed therapy with esca-
lated doses of BEACOPP. Of this subgroup, only 11.1% (risk
difference in relapse rate) of patients will beneﬁt from this
treatment intensiﬁcation. Consequently, only 0.188 3 0.111 3
100% 5 2.1% of patients who undergo interim FDG-PET will
beneﬁt from this approach, because treatment de-escalation in
interim FDG-PET–negative cases is considered infeasible. This
high number of patients needed to scan would result in major
increases in costs, radiation exposure, and patient discomfort.
The outcome beneﬁt of this approach is further nulliﬁed by the
fact that the majority of cases in which ﬁrst-line therapy fails can
be cured by second-line therapies. This is reﬂected by the ﬁnding
that, despite the large sample size and long minimum follow-up
time, no beneﬁt in overall survival (P5.062) was observed.1 Note
that the beneﬁt of this approach will be even lower in the sub-
group of favorable Hodgkin lymphoma, because of the lower
incidence of interim FDG-PET–positive patients in this sub-
group1 and the presumption that it is not unlikely that prognosis
is better in this subgroup even if standard, nonintensiﬁed therapy
is applied. It is not unlikely that other cheap and readily available
predictive biomarkers, such as the presence of two or more Eu-
ropean Organisation for Research and Treatment of Cancer risk
factors, will be able to provide comparable prognostic value andmay
consequently be better surrogates for deciding when to adapt
treatment.
In conclusion, an interim FDG-PET–adapted therapeutic
approach in early-stage Hodgkin lymphoma exposes all patients
to more imaging-related ionizing radiation, subjects a consid-
erable proportion (ie, all interim FDG-PET–positive patients) to
intensiﬁed therapy, and will provide beneﬁt to only a small
minority of patients whose disease relapse will be avoided.
Furthermore, overall survival is not improved, and health care
costs will increase considerably. Therefore, interim FDG-PET–
adapted therapy is not an efﬁcient approach to improving
outcome.
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